Title:
COMBINATION DRUG OF ANTI-EPIREGULIN ANTIBODY AND ANTI-EGFR ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2018/034301
Kind Code:
A1
Abstract:
The present invention pertains to a combination therapy of an anti-epiregulin antibody and an anti-EGFR antibody in cancer treatment. The present invention demonstrates for the first time a synergistic effect when the anti-epiregulin antibody and the anti-EGFR antibody are used in combination.
Inventors:
ISHII NOBUYA (JP)
ONO MEI (JP)
WATANABE YOSHINORI (JP)
IWASAKI JUNKO (JP)
ONO MEI (JP)
WATANABE YOSHINORI (JP)
IWASAKI JUNKO (JP)
Application Number:
PCT/JP2017/029425
Publication Date:
February 22, 2018
Filing Date:
August 16, 2017
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K39/395; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| WO2015078906A1 | 2015-06-04 | |||
| WO2010137654A1 | 2010-12-02 |
Foreign References:
| US20150110793A1 | 2015-04-23 | |||
| US20160002741A1 | 2016-01-07 |
Other References:
TAKAHASHI N ET AL.: "Serum Levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer", BRITISH JOURNAL OF CANCER, vol. 110, 2014, pages 2716 - 2727, XP055350592
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: